KYMR

Kymera Therapeutics, Inc. (KYMR) - 2025 Annual Report (10-K) Summary

Business Context and Reporting Period

Company: Kymera Therapeutics, Inc.
Reporting Period: Fiscal year ended December 31, 2025.
Business Model: Clinical-stage biopharmaceutical company focused on Targeted Protein Degradation (TPD) to develop oral medicines for immunology and oncology. The company has no product sales revenue and relies on collaboration agreements and equity financing.

Key Financial Metrics (Year Ended Dec 31, 2025)

Liquidity: As of December 31, 2025, the company held $1,619.4 million in cash and marketable securities. Management estimates this is sufficient to fund operations into 2029.

Material Changes vs. Prior Period

• Revenue Decline: Collaboration revenue decreased by $7.9 million (17%) primarily due to the satisfaction of performance obligations under the Sanofi agreement in Q2 2025, partially offset by new revenue from the Gilead agreement.
• Expense Increase: R&D expenses increased by $76.3 million (32%), driven by a $46.8 million increase in costs for the STAT6 program (KT-621) and higher personnel/overhead costs.
• Capital Raise: The company raised approximately $928.9 million net from the issuance of common stock and pre-funded warrants in 2025 (June and December offerings), significantly bolstering its cash position compared to 2024.
• Collaboration Milestones: Sanofi exercised its full participation election for the IRAK4 program (KT-485) in June 2025, discontinuing the development of the previous candidate (KT-474). A new collaboration with Gilead for CDK2 degraders was announced in June 2025, generating a $40 million upfront payment.

Guidance, Outlook, and Risks

Outlook: The company expects to continue incurring significant operating losses as it advances clinical programs. It anticipates advancing at least one new molecular entity into clinical testing annually.

Key Pipeline Updates:

• STAT6 (KT-621): Initiated Phase 2b trials (BROADEN2 for Atopic Dermatitis and BREADTH for Asthma). Received Fast Track Designation for Atopic Dermatitis in December 2025. Phase 1b data showed robust STAT6 degradation and biomarker modulation comparable to dupilumab.
• IRF5 (KT-579): Initiated Phase 1 clinical trial in healthy volunteers.
• IRAK4 (KT-485): Sanofi plans to advance into clinical testing in 2026.
• CDK2: New collaboration with Gilead to develop molecular glue degraders; Kymera leads discovery/preclinical research.

Material Risks:

• Capital Needs: Continued reliance on equity financing or collaborations; inability to raise capital could force delays or discontinuation of programs.
• Clinical Uncertainty: Early-stage clinical data (e.g., KT-621 Phase 1b) is not predictive of later-stage success. Failure in Phase 2b trials would materially harm the business.
• Regulatory & Policy: Risks related to FDA review timelines, potential government shutdowns (noted in Oct 2025), and changing healthcare policies (e.g., Inflation Reduction Act, potential tariffs).
• Collaboration Dependence: Future revenue and development timelines depend heavily on Sanofi and Gilead exercising options and meeting milestones.

Investor Verification Checklist

• Cash Runway: Verify the $1.6 billion cash balance and the specific assumptions used to project funding sufficiency into 2029.
• KT-621 Phase 2b Design: Review the specific endpoints and comparator arms for the BROADEN2 and BREADTH trials to assess the statistical power for proving superiority or non-inferiority to biologics.
• Sanofi IRAK4 Transition: Confirm the timeline for Sanofi's initiation of clinical testing for KT-485 in 2026 and the specific milestones triggering future payments.
• Gilead Option Exercise: Monitor the progress of the CDK2 preclinical data package delivery, as Gilead's option exercise (and subsequent $45 million payment) is contingent on this.
• Lease Obligations: Review the $112.8 million in future lease commitments and the status of subleasing the vacated Watertown facility to mitigate impairment risks.